Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical Trial.

Brian A Willis,Albert C Lo,Jeffrey L Dage,Sergey Shcherbinin, Louise Chinchen,Scott W Andersen,Elizabeth S LaBell,David G S Perahia,Paula M Hauck,Stephen L Lowe

Journal of Alzheimer's disease reports（2023）

引用 0|浏览2

暂无评分

摘要

No dose-limiting adverse events were observed with zagotenemab treatment. Pharmacokinetics of zagotenemab were typical for a monoclonal antibody. Meaningful pharmacodynamic differences were not observed.Clinicaltrials.gov: NCT03019536.

查看译文

关键词

symptomatic alzheimers,zagotenemab,alzheimers disease,pharmacokinetics

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要